Accelerated step-up infliximab use is associated with sustained primary response in pediatric Crohn's disease
Digestive Diseases and Sciences Mar 21, 2018
Ling J, et al. - Authors sought to analyze the correlation between the time of introduction of infliximab (IFX) in Crohn’s disease (CD) with a sustained remission. Yielded data demonstrated that the early step-up use of IFX in children with CD with inadequate clinical response to conventional therapies gave rise to sustained primary response over 2 years.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
